DOTATATE PET for Meningioma Radiation Planning

Launched by BRITISH COLUMBIA CANCER AGENCY · Apr 15, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way doctors plan radiation therapy for patients with meningioma, a type of brain tumor. The study is investigating a new imaging technique using a special substance called 68Ga-DOTATATE-PET, which can provide clearer and more detailed images of the tumor compared to the standard MRI scans. By using this advanced imaging, doctors hope to better target the tumor during radiation treatment, which could help minimize damage to healthy tissue and improve treatment outcomes.

To participate in the trial, individuals must be at least 18 years old and have a meningioma that requires radiation treatment, either because it's a new tumor or because it's a recurring one after surgery. They should not have received any previous radiation or specific medical treatments for the tumor. Participants will undergo procedures to help with radiation planning and will be closely monitored throughout the study. It’s important to note that individuals who are pregnant, breastfeeding, or have certain conditions that prevent them from lying still may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• • Able and willing to comply with the study procedures
• • Intact meningioma requiring definitive radiation
• • Post-operative meningioma requiring adjuvant radiation
• • No prior radiation therapy or medical therapy directed at the tumour
• Exclusion Criteria:
• • Breastfeeding or pregnancy
• • Claustrophobia or inability to lie still in a supine position
• • Unwillingness or inability to provide informed consent